Akari Therapeutics, Plc (AKTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 10.94 |
| Open | 11.47 |
| Day High | 11.79 |
| Day Low | 10.56 |
| 52-Week High | 49.6 |
| 52-Week Low | 3.02 |
| Volume | 204,550 |
| Average Volume | 784,760 |
| Market Cap | 12.85M |
| PE | -4.35 |
| EPS | -2.58 |
| Moving Average 50 Days | 8.81 |
| Moving Average 200 Days | 15.99 |
| Change | 0.29 |
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
GlobeNewswire Inc.
Feb 26, 2026 2:10 PM GMT
Recognized expert in cancer biology, RNA biology and translational therapeutics with 20 years of experience in preclinical oncology drug discovery and developmentTAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nas
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board
GlobeNewswire Inc.
Feb 23, 2026 1:50 PM GMT
Dr. Anczukow is a leading cancer biologist with expertise in RNA biology, molecular and cell biology, as well as human genetics, cancer biology, and genomics Olga Anczukow, Ph.D. Olga Anczukow, Ph.D. TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference
GlobeNewswire Inc.
Feb 18, 2026 2:05 PM GMT
In-person presentation on Wednesday, February 25th at 11:00 AM PT TAMPA, Fla. and LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with no